The National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, founded in 1891, is one of the world’s leading research institutes in its area.
The center possesses a unique collection of viruses, and has its own vaccine production line. The N.F. Gamaleya Center has successfully engineered and registered two vaccines for the Ebola fever using adenovirus vectors. Read more
Media about us
August 12, 2020 Russia’s Minister of Health M. A. Murashko held a press briefing on the first registered COVID-19 vaccine. Read more
July 23, 2020 A long interview with the Deputy Director of the Research Center, Corresponding Member of the Russian Academy of Sciences D. Yu. Logunov about the development of Russia’s first Covid-19 vaccine. Read more
June 18, 2020 The Covid-19 vaccine, developed by the N.F. Gamaleya Research Center for for Epidemiology and Microbiology of the Ministry of Health of Russia, was administered to the first group of volunteers. Read more
June 16, 2020 The Ministry of Health of Russia issued permission to conduct clinical trials of two forms of the vaccine against the new coronavirus infection COVID-19, developed at the FSBI National Research Center for Epidemiology and Microbiology named after the hono. Read more
View all
A tried-and-true technology using vectors that incorporate human adenoviruses

The use of adenovirus vector technology for vector vaccines has been gaining momentum since the 1980s, and is safe and effective, which has been proven in multiple studies.

Read more
The first registered vaccine against COVID-19

On 11 August, the Russian Federation Ministry of Health issued a certificate of registration with the number LP-006395 for a vaccine to help prevent the novel coronavirus infection COVID-19, developed by the Russian Ministry of Health N.F. Gamaleya National Research Center for Epidemiology and Microbiology.

Read more
Gamaleya Ebola vaccine

In December 2015, the Russian Ministry of Health registered the first 2 domestically-produced vaccines against the Ebola hemorrhagic fever. Both these vaccines were engineered at the Russian Ministry of Health N.F. Gamaleya Federal Scientific Research Center of Epidemiology and Microbiology, and passed jointly held preclinical trials, and clinical trials, at institutions run by the Russian Ministry of Health and Ministry of Defense.

Read more